[Clinical-neuroleptic investigation of N-((1-ethyl-pyrrolidine-2-yl)-methyl)-2-methoxy-5-sulfamyl-benzamide-neuroleptic sulpiride (Dogmatil) in acutly ill schizophrenics].
D000293:Adolescent; D000328:Adult; D000368:Aged; D001480:Basal Ganglia Diseases / Q000139:chemically induced / Q000188:drug therapy; D001712:Biperiden / Q000627:therapeutic use; D001794:Blood Pressure / Q000187:drug effects; D002986:Clinical Trials as Topic; D004341:Drug Evaluation; D004644:Emotions / Q000187:drug effects; D005260:Female; D006212:Hallucinations / Q000188:drug therapy; D006801:Humans; D008297:Male; D008875:Middle Aged; D009043:Motor Activity / Q000187:drug effects; D011674:Pulse / Q000187:drug effects; D012559:Schizophrenia / Q000188:drug therapy*; D013469:Sulpiride / Q000008:administration & dosage / Q000009:adverse effects / Q000097:blood / Q000494:pharmacology / Q000627:therapeutic use*
D001712:Biperiden; D013469:Sulpiride
Klinisch-neuroleptische Untersuchung des N-((1-Athyl-pyrrolidin-2-yl)-methyl)-2-methoxy-5-sulfamoyl-Benzamid-Neuroleptikums Sulpirid (Dogmatil) an akut erkrankten Schizophrenen